Patents by Inventor Yingying Jin

Yingying Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240126936
    Abstract: A multi-scale aggregation pattern analysis method for a complex traffic network is provided, which belongs to the field of the highway traffic network. Firstly, an adjacency matrix, a position attribute matrix, a distance weight matrix, a road grade matrix, and a time-phased traffic congestion degree matrix of a highway traffic network are calculated; secondly, a weight influence factor of the road network is incorporated based on a PageRank algorithm to determine order of critical nodes; finally, a two-dimensional decision diagram is drawn by two indicators: order of critical nodes and a shortest path distance. A new weighting matrix which accords with the actual situation of the road network is obtained by incorporating a position weight matrix, a distance weight matrix, a road grade weight matrix and a dynamic traffic congestion degree weight matrix based on a similarity matrix of the spectral clustering.
    Type: Application
    Filed: January 5, 2023
    Publication date: April 18, 2024
    Inventors: Xia Zhu, Yingying Pei, Yongtao Jin, Guohong Li, Yulong Hao, Yuanping Liu, Yuyan Liu, Longfang Duan, Cui Jia, Qiyue Liu, Tao Ma, Shan An, Jia Xi, Zhihong Song
  • Publication number: 20220033476
    Abstract: Disclosed is a fusion protein of a mutated recombinant single-chain human coagulation factor VIII (FVIII), a preparation method therefor, and a use thereof. The fusion protein sequentially comprises, from an N-terminus to a C-terminus, a mutated single-chain human FVIII having a partially deleted B-domain, a flexible peptide linker, at least one rigid unit of a carboxyl-terminal peptide of a human chorionic gonadotropin beta subunit, and a half-life prolonging moiety (preferably an IgG Fc variant). The fusion protein has a similar biological activity to a recombinant FVIII, a prolonged active half life in vivo, and better stability in vitro and in vivo, and thus improves the pharmacokinetics and efficacy of the fusion protein.
    Type: Application
    Filed: September 24, 2019
    Publication date: February 3, 2022
    Inventors: Yongjuan Gao, Shixiang Jia, Yuncheng Zheng, Yingying Jin, Zhu Wang, Zhao Dong, Si Chen, Bill Nai-chau Sun, Qiang Li
  • Publication number: 20210371526
    Abstract: Provided is a tetravalent homodimeric bispecific antibody molecule simultaneously targeting an immune effector cell antigen CD3 and a tumor-associated antigen, wherein the bispecific antibody molecule contains, in order from N-terminus to C-terminus, a first single chain Fv, a second single chain Fv and a Fc fragment; wherein the first single chain Fv can specifically bind to the tumor-associated antigen, the second single chain Fv can specifically bind to CD3, and the first and the second single chain Fvs are connected by a linker peptide, while the second single chain Fv and the Fc fragment are directly connected or connected by a linker peptide; and the Fc fragment does not have effector functions such as CDC, ADCC and ADCP.
    Type: Application
    Filed: October 31, 2019
    Publication date: December 2, 2021
    Inventors: Qiang Li, Xinlu Ma, Shixiang Jia, Yuan Yan, Yuhua Zhang, Li Zhou, Rilong Sun, Xueyuan Cui, Lingju Yu, Yujie Yan, Yingying Jin, Yao Xiong, Yuanli Li, Si Chen, Xuemei Liu, Jiasheng Diao